Atara Plans FDA Type A Meeting on EBVALLO

The latest update is out from Atara Biotherapeutics ( (ATRA) ).

On March 12, 2026, Atara Biotherapeutics announced that it has scheduled a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued on January 9, 2026, for the Biologics License Application of its product EBVALLO. The scheduled meeting marks a key regulatory step for Atara as it works to address the FDA’s concerns and determine a potential path forward for tabelecleucel’s approval in the U.S. market.

The most recent analyst rating on (ATRA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Spark’s Take on ATRA Stock

According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.

The score is primarily held down by weak financial performance (negative equity and ongoing cash burn) and very bearish technicals (price far below key moving averages with negative MACD). A highly negative corporate event (FDA CRL for EBVALLO) further increases risk, while the low P/E provides only partial support given the underlying uncertainty.

To see Spark’s full report on ATRA stock, click here.

More about Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies, including tabelecleucel, for serious diseases. The company operates in the biopharmaceutical industry with an emphasis on advanced biologics aimed at addressing significant unmet medical needs in its target patient populations.

Average Trading Volume: 444,245

Technical Sentiment Signal: Sell

Current Market Cap: $44.92M

For detailed information about ATRA stock, go to TipRanks’ Stock Analysis page.